Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.20K | 16.10K | 23.50K | 111.10K | 201.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.20K | 16.10K | 23.50K | 111.10K | 201.50K |
| Cost of Revenue | 4.60K | 138.50K | 262.50K | 264.10K | 265.70K |
| Gross Profit | 3.60K | -122.30K | -238.90K | -152.90K | -64.10K |
| SG&A Expenses | 2.89M | 3.45M | 3.95M | 3.51M | 3.08M |
| Depreciation & Amortization | 50.20K | 141.00K | 223.10K | 223.10K | 223.10K |
| Other Operating Expenses | -5.59M | -4.98M | -4.46M | -1.33M | 1.80M |
| Total Operating Expenses | -1.08M | 306.80K | 1.54M | 4.35M | 7.21M |
| Operating Income | 1.09M | -290.60K | -1.51M | -4.24M | -7.01M |
| Income Before Tax | 3.84M | 2.46M | 1.24M | -2.87M | -7.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.84 | 2.46 | 1.24 | -2.87 | -7.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.84M | 2.46M | 1.24M | -2.87M | -7.03M |
| EBIT | 1.09M | -290.60K | -1.51M | -4.24M | -7.01M |
| EBITDA | 1.18M | -107.70K | -1.25M | -3.92M | -6.66M |
| EPS Basic | 0.09 | 0.05 | 0.02 | -0.07 | -0.17 |
| Normalized Basic EPS | 0.02 | -0.01 | -0.03 | -0.07 | -0.11 |
| EPS Diluted | 0.07 | 0.04 | 0.01 | -0.08 | -0.17 |
| Normalized Diluted EPS | 0.01 | -0.01 | -0.03 | -0.07 | -0.11 |
| Average Basic Shares Outstanding | 177.79M | 174.43M | 171.09M | 168.39M | 165.69M |
| Average Diluted Shares Outstanding | 191.74M | 188.38M | 185.04M | 175.36M | 165.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |